Artificial Intelligence has the potential to reduce the time and cost of the R&D process and clinical trials.
Our Core lab solution, Catalyst, leverages AI to automate the assessment of echocardiogram images, eliminating the variability with all ultrasound machines and centralizing analysis for any multi-center clinical trial. The system allows a single analysis program to be used with all ultrasound machines.
Enhances retrospective
datasets to improve analysis
Full automation reduces user
error and ensures accuracy
Rapid, highly reproducible reports within 90 mins
Multiple classifiers for disease specific algorithms tailored to your needs
Catalyst uses machine learning algorithms trained on hundred of thousands of clinical examples, through extracting thousands of hidden and complex imaging features not noticeable in conventional visual inspection. As a result, it provides highly accurate and reproducible calculations to power the statistical outcomes of the trials.
Our technology is the only software that can process both stress and resting echo, with or without strain calculation, with the automation providing the flexibility to perform retrospective data analysis.
Standardizing echocardiography reads for prospective multi-center clinical trials
BSE accredited echocardiographers
Standard Corelab reporting using TomTec or EchoPAC
Fast turnaround time and customisable
Provides connectivity setup and site training
Eliminates operator and vendor variabilities
Increases sensitivity and accuracy to detect changes
Reduces trial size with the same statistical outcomes
Widens patient pool for recruitment
Automation provides analysis results in as little as 90 seconds per study
Ability to re-analyse large retrospective datasets for additional imaging parameters
Ideal for large, completed studies
The technology has been validated and developed through our partnership in the EVAREST trial with the NHS in the UK, one of the largest ultrasound programs in the world. It’s trained on past clinical examples, to spot thousands of features, compared to a handful of indicators in traditional visual inspection. The EVAREST validation trial continues to run in over 30 NHS hospitals and has recruited over 6000 patients to date.
Accuracy and precision was assessed against EF, GLS and LV volumes produced by other commercially available software that required manual contouring. Images were processed by five trained professionally accredited operators*.
It was shown to provide accurate and robust measurements of EF, GLS and LV volumes. Inter-operator* variability demonstrated zero variability when using automated program.
*BSE accredited echocardiographers and board certified physicians.